Two Rutgers engineers specializing in the process of making drugs derived from living organisms have created an analytical tool they expect will accelerate the discovery and production of biologic drugs that are often at the cutting edge of biomedical research. In an article that is the cover story in the American Chemical Society journal, Analytical…
Rebuilding from the ground up: powering drug deformulation via analytical technologies
By Rob Taylor, Pharmaceutical Segment Manager, Malvern Panalytical Sometimes you must take things apart to rebuild them. For a child with a LEGO masterpiece, this can be heartbreaking. But in the world of pharmaceuticals, reverse-engineering drugs is crucial for the development of less expensive, more accessible generic products. Chemical and structural reverse engineering, also known…
2022 Global Funding Forecast: Strong R&D growth with clouds on the horizon
For 2022, U.S. industrial organizations are expected to collectively invest $447 billion in R&D efforts, or about 65.8% of the total R&D monies invested by the U.S. ($679.4 billion). That industrial investment is more than all other global countries except for China. The U.S. federal government is expected to invest $181.4 billion in R&D in…
2022 Global Funding Forecast: R&D variants cover more than the pandemic
Researchers live in a world of variants — coronaviral variants are taking center stage in the media right now. But in 2022, researchers will also have to deal with the challenges of accelerating economic inflation rates, global warming, electrification of everything, fifth- and sixth-generation broadband uncertainties, declining animal and plant diversities, declining global population rates,…
PerkinElmer to showcase accelerated cancer research at AACR Annual Meeting
PerkinElmer. will be at The American Association for Cancer Research (AACR) Annual Meeting from April 8-13 in New Orleans (booths #1009, #1851 and #909), alongside its partner companies showcasing how genomic and cellular solutions for cancer research can be used to study its mechanisms, improve biomarker discovery, and help drive targeted, therapeutic discovery leading to…
Sepha’s new EZ Blister+ enables 21 CFR Part 11 compliant micro-batches
Sepha, the Northern Ireland-based manufacturer of pharmaceutical packaging and equipment, has developed a new compact small-batch blister packaging machine with full traceability and electronic data storage capabilities. The EZ Blister+ meets increased demand for 21 CFR Part 11 compliant micro-batches throughout the blister production lifecycle, from R&D right through to commercial production. It will launch…
GenNext Technologies receives $2.5M grant to commercialize in-cell protein footprinting instrumentation
GenNext Technologies, a growth-stage company providing biopharmaceutical drug discovery systems and services, announced the receipt of a two year, Phase II SBIR grant for a project titled “In-Cell Automated Flash Oxidation (IC-AutoFox) Protein Footprinting System.” The grant was awarded by the National Institute of General Medical Systems (NIGMS) of the U.S. Department of Health and…
Genomenon raises $20M Series B financing, launching a new era in AI-powered genomic data
Genomenon Inc., an AI-driven genomics company, announces the completion of a $20 million Series B financing round. The funds will expand the company’s commercial operations and the development of its genomic data hub, which serves genetic testing labs, hospitals, pharmaceutical, and biopharma companies. Genomenon leverages AI (Artificial Intelligence) to organize the world’s genomic knowledge and…
Thermo Fisher Scientific continues collaboration to support biopharmaceutical discovery and development
Thermo Fisher Scientific and Symphogen, an affiliate of the pharmaceutical company Servier, announce the continuation of their collaboration to provide biopharmaceutical discovery and development laboratories with innovative tools and streamlined workflows for efficient characterization of complex therapeutic proteins. Since the collaboration began in 2018, Symphogen has adopted new and innovative instruments and software to improve…
DuPont invests in bioprocessing supply chain to enhance drug development purchases
DuPont has launched a new online sales portal tailored to the needs of bioprocessing industry purchasers. The portal handles online sales transactions, with target lead times of less than one week. DuPont’s bioprocessing solutions enable sophisticated purifications and separations for therapeutics and diagnostics, with brands such as DuPont AMBERCHROM and DuPont AMBERLITE being well established…
US Centers for Disease Control guidance includes EUROIMMUN assay in its two-step testing algorithm for dengue virus
EUROIMMUN, a PerkinElmer company, announces that its EUROIMMUN Anti-Dengue Virus NS1 Type 1-4 ELISA (IgG) (research use only) was cited by the U.S. Centers for Disease Control and Prevention (CDC) as part of the two-step testing algorithm guidance for pre-vaccination screening for the Dengvaxia vaccine that is used to prevent future dengue disease. According to…
Proscia and Datavant partner to connect pathology data with health data ecosystem for life sciences R&D
Proscia, the digital and computational pathology solutions provider, and Datavant, which securely connects organizations with health data, have announced a partnership that will provide life sciences companies with digitized pathology data to power the development of novel therapeutics and diagnostics. The partnership brings together Datavant’s privacy-preserving connectivity technology and the largest U.S. health data ecosystem…
A cool game for one hot competitor — the 2021 Freezer Challenge
International Freezer Challenge honors Univ. of Illinois with 2021 “Winning Streak Award.” By Becky Chambers Hennessy, contributing writer (This is part two of a two-part series. Read part one, Facing sustainability in the lab, here.) The University of Illinois Urbana-Champaign is continuing a hot streak in arguably the coolest competition around. The university was recognized…
Facing sustainability in the lab
By Becky Chambers Hennessy, contributing writer Scientific research leaders are taking a long look in the mirror. They see their laboratories as home to beneficial scientific breakthroughs, in areas from epidemiology and the coronavirus to climate change and greenhouse gases. They’re also recognizing them as resource-intensive spaces with enormous carbon footprints. It’s an irony that’s…
Pistoia Alliance president warns pharmaceutical industry not to undo advances made during pandemic
Dr. Steve Arlington, president of The Pistoia Alliance, a global not-for-profit advocating for greater collaboration in biopharma, is calling on the pharmaceutical industry to continue building on the advances in collaboration it has built over the past two years. Digital transformation has accelerated rapidly during the pandemic, which in turn has greatly improved remote patient…
ProQR announces Axiomer RNA editing licensing and research collaboration with Lilly
ProQR Therapeutics N.V. has announced a global licensing and research collaboration with Eli Lilly and Company (Lilly) focused on the discovery, development and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The companies will use ProQR’s proprietary Axiomer RNA editing platform to progress new drug targets toward clinical development and…
Thermo Fisher Scientific and AstraZeneca to co-develop NGS-based companion diagnostics
Thermo Fisher Scientific‘s clinical sequencing business and AstraZeneca announced they will co-develop next-generation sequencing (NGS)-based companion diagnostics (CDx) to support AstraZeneca’s expanding portfolio of targeted therapies. The companies will collaborate under a multiyear, global agreement. “As the pipeline of targeted therapies expands, the availability of diagnostic tools that can interrogate multiple biomarkers simultaneously will ensure…
Revelation Biosciences to become publicly traded through merger with Petra Acquisition
Revelation Biosciences (Revelation), a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, and Petra Acquisition, a special purpose acquisition company, announces they have entered into a definitive merger agreement for a business combination that will result in Revelation Biosciences becoming a publicly traded company. An…
Fusion Antibodies joins Eurofins Discovery to support preclinical drug discovery research
Fusion Antibodies, a specialist in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that is has entered into a commercial collaboration with Eurofins, a Eurofins Scientific SE group company; a provider of products and services to the drug discovery industry. As leading global innovation-driven and customer-focused providers of antibody…
Bioluminescent research tools showcased at global seminar series
Life science and drug discovery researchers interested in bioluminescent tools will have the opportunity to hear from global thought leaders on the possibilities and applications of luciferase technologies during the upcoming Discover Glo 2021 virtual seminar series. Hosted by Promega and held September 13-16, the series will advance understanding in important therapeutic areas such as…
High-speed camera captures a water jet’s splashy impact as it pierces a droplet
By Jennifer Chu | MIT News Office Squirting a jet of water through a drop of liquid may sound like idle fun, but if done precisely, and understood thoroughly, the splashy exercise could help scientists identify ways to inject fluids such as vaccines through skin without using needles. That’s the motivation behind a new study…
Hot-melt extrusion produces predictable, high drug-loading amorphous solid dispersions
Recent work by a team of researchers at Queen’s University Belfast and University College London reports on a newly developed strategy for the manufacture of a high drug loaded amorphous solid dispersion (HDASD) using a hot-melt extrusion (HME) based platform(1). Around 80% of new drug candidates that emerge are classified as poorly soluble(2). Enhancement of…
C. Light receives funding and support from the ADDF to pilot early retinal biomarker study
C. Light Technologies, a neurotech and AI company, announces it has received an investment from the Alzheimer’s Drug Discovery Foundation (ADDF) through its Diagnostics Accelerator, a collaborative research initiative supported by Leonard A. Lauder, Bill Gates, the Dolby family, the Charles and Helen Schwab Foundation, Jeff Bezos and MacKenzie Scott among other leading philanthropists. This…
PerkinElmer expands KRAS oncology drug discovery assays with new ready-to-use AlphaLISA kits
PerkinElmer announced they have four new ready-to-use AlphaLISA KRAS kits, designed to help scientists better understand complex KRAS protein structures and mutations so they can more easily, quickly and precisely identify potential new therapeutic candidates for a wide range of prevalent cancers. Researchers will now be able to choose between PerkinElmer’s HTRF or AlphaLISA assays…
Atlas Antibodies AB acquires evitria, provider of recombinant antibody expression
Atlas Antibodies has agreed to acquire evitria, developer of transient recombinant antibody expression in CHO cells. This transformative acquisition brings together a leading provider of highly validated research antibodies and a front-runner in the field of custom recombinant antibody expression. Since its inception in 2010, evitria has been singularly focused on transient expression of recombinant…